news
Treating HCC with genetically modified NK-cell therapy
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
List view / Grid view
In Vitro
webinar
CRISPR™ MDCKII cell lines development for bioavailability and DDI assessments
17 July 2024 | By Eurofins Discovery
Join this webinar to hear from Eurofins Discovery on the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines
article
Brain organoids: a fascinating and powerful tool for drug discovery
Human brain organoids are complex in vitro tools derived from stem cells, designed to model the molecular basis of neurodevelopment and the pathogenesis of neurological disorders. By mimicking the function of the human brain, in both health and disease, their application in drug discovery holds significant potential for identifying new…
news
Novel inhibitor developed to combat HER2-positive breast cancer
The inhibitor, HVH-2930, effectively induced apoptosis in breast cancer cells without initiating the heat shock response.
webinar
The value of GPCR cell-based assays in drug discovery
20 June 2024 | By Eurofins DiscoverX
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
news
Werner syndrome: mechanism behind atherosclerosis elucidated
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
news
Macrophage-mediated phagocytosis: treating solid tumours
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
news
Novel version of CRISPR gene-editing protein engineered
Researchers have developed a new, compact EbCas12a variant that can be packaged into an all-in-one AAV system with its crRNA.
article
Improving treatment responses to solid tumours with trispecific TCEs
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
article
Enhancing gene therapy with Circio
In this Q&A, Erik Wiklund, CEO of Circio, explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy.
news
Ovarian cancer: CBR-5884 demonstrates promising antitumour effects
In assays and patient-derived organoids, the small molecule inhibitor CBR-5884 successfully treated epithelial ovarian cancer.
news
How gKetoC alleviates intestinal inflammation
Through in vitro and in vivo models, researchers find a mechanism by which bacteria-generated fatty acids regulate immune responses.
article
Assay design for Alzheimer’s disease: key considerations and emerging trends
In this Q&A, we speak to Dr Emma Murphy, Head of Biology at the Alzheimer’s Research UK Oxford Drug Discovery Institute. Among her many insights, she discusses how the challenges in developing reproducible assays can be addressed, as well as strategies used to translate promising findings into clinically relevant tools…
news
The effect of ovarian stimulation on IVF outcomes
In mouse models, the differences between oocytes collected by natural or stimulated approaches were investigated.
news
Exploring the conditions in which pathological 4R tau misfolds
Researchers have presented new findings that offer potential pathways to arrest critical steps toward the accumulation of mutant tau.
